By Mill Chart
Last update: Apr 30, 2024
Unearth the potential of NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) as a dividend stock recommended by our stock screening tool. NYSE:NVO maintains a robust financial footing and delivers a sustainable dividend. We'll delve into the details below.
To gauge a stock's dividend quality, ChartMill utilizes a Dividend Rating ranging from 0 to 10. This comprehensive assessment considers various dividend aspects, including yield, history, growth, and sustainability. NYSE:NVO has achieved a 7 out of 10:
ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NYSE:NVO, the assigned 7 reflects its health status:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NYSE:NVO has earned a 9 out of 10:
Our Best Dividend screener lists more Best Dividend stocks and is updated daily.
Check the latest full fundamental report of NVO for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (5/16/2024, 7:08:01 PM)
Premarket: 131.54 -1.5 (-1.13%)133.04
-1.62 (-1.2%)
Could Amgen be the next stock to soar due to a GLP-1 drug?
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for quality investing?
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days.
This company is serious about maintaining its leadership.
Both of these businesses are finding traction in a pair of major markets.
This mid-cap biopharma may one day be a titan of the industry.
These three companies could soon be the next bargain stocks to buy as the market adjusts to their developing situations.
These stocks are both experts in their respective fields.
These pharmaceutical companies are top-notch dividend growth stocks for the future.
While people tend to be too cool for school regarding groupthink, these popular stocks among retail investors could change perceptions.